Bristol-Myers Squibb Just Got Crucial FDA Backing On Alzheimer’s Psychosis Program; What’s NEXT?

Bristol-Myers Squibb Co. reported its third-quarter 2025 financial results, highlighting strong performance across its growth portfolio and maintaining focus on its long-term growth strategy. The company’s revenue reached approximately $12.2 billion, driven by a 17% increase in sales from its growth portfolio, which includes key drugs such as Opdivo, Reblozyl, Camzyos, and Breyanzi. Given these strong results, Bristol-Myers Squibb has raised its full-year revenue guidance, highlighting confidence in its current portfolio. On the positive side, the company saw notable successes in its oncology and hematology segments. Opdivo, a key component of its cancer portfolio, demonstrated a 6% growth in global sales, bolstered by strong launches in several indications such as MSI-high colorectal cancer and first-line non-small cell lung cancer. Additionally, Reblozyl’s sales rose by 38% in the U.S., and Breyanzi’s global sales surged by 58% due to strong demand across its indications.